How Much Is Compound Semaglutide: Real-World Pricing, Hidden Costs, and What Actually Determines Your Monthly Bill

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compound semaglutide costs $199 to $499 per month depending on dose tier, provider business model, and whether you're paying cash or using insurance adjudication
• The price difference between 0.5 mg weekly and 2.4 mg weekly is typically $100 to $150 per month, not proportional to dose strength
• Brand-name Wegovy costs $1,349 per month without insurance, making compounded versions 73% to 85% cheaper at equivalent doses
• Hidden costs include required provider visits ($49 to $99 per consultation), shipping fees, and mandatory lab work at some platforms

Direct answer (40-60 words)

Compound semaglutide costs between $199 and $499 per month as of April 2026. Starting doses (0.25 mg to 0.5 mg weekly) typically cost $199 to $249. Maintenance doses (1.0 mg to 2.4 mg weekly) cost $299 to $499. Price depends on dose tier, provider platform, pharmacy source, and whether B12 or other additives are included.

Table of contents

1. The pricing spectrum: what you'll actually pay
2. What most pricing guides get wrong about compound semaglutide costs
3. The dose-price relationship: why higher doses don't cost proportionally more
4. Brand-name vs compounded: the real cost comparison
5. Hidden costs that turn a $249 advertised price into $380
6. The three pricing models: subscription, pay-per-fill, and hybrid
7. Insurance, FSA, and HSA: what's reimbursable and what's not
8. Geographic price variation and pharmacy sourcing
9. The FormBlends pricing framework: how we think about transparent cost structure
10. When cheaper is actually more expensive: the false economy of under-dosing
11. How to calculate your true monthly cost
12. FAQ
13. Sources

The pricing spectrum: what you'll actually pay

As of April 2026, compound semaglutide pricing clusters into three tiers:

Dose range	Typical monthly cost	Common provider examples
0.25 mg to 0.5 mg weekly (starting doses)	$199 to $249	Most telehealth platforms during titration
1.0 mg to 1.7 mg weekly (mid-range maintenance)	$279 to $349	Standard maintenance pricing
2.0 mg to 2.4 mg weekly (maximum dose)	$399 to $499	Premium tier or high-dose programs

The price you pay depends on five variables:

1. Dose tier. Most platforms use 3 to 4 pricing tiers rather than continuous dose-based pricing.
2. Provider business model. Subscription platforms (monthly recurring) vs pay-per-fill models vs hybrid approaches.
3. Pharmacy source. Large-scale 503B outsourcing facilities vs smaller 503A compounding pharmacies have different cost structures.
4. Additives. Semaglutide-only formulations vs semaglutide + B12 vs semaglutide + B6/B12/L-carnitine blends.
5. Consultation structure. Platforms that bundle provider visits into the medication cost vs those that charge separately.

The advertised "$199/month" price almost always refers to the starting dose (0.25 mg or 0.5 mg weekly), not maintenance doses. A patient reaching 2.4 mg weekly will pay $399 to $499 per month at most platforms.

What most pricing guides get wrong about compound semaglutide costs

The single most common error in published pricing content is treating compound semaglutide as a commodity with uniform pricing. The claim "compound semaglutide costs $250 per month" appears in dozens of articles and is wrong in a specific, correctable way.

The error conflates starting-dose pricing with maintenance-dose pricing. A patient beginning treatment at 0.25 mg weekly may pay $199 to $249 for the first 8 to 12 weeks. The same patient at 2.4 mg weekly maintenance will pay $399 to $499. The average monthly cost over a 12-month treatment course is $320 to $380, not $250.

The second common error is ignoring consultation fees. Many platforms advertise medication-only pricing but require monthly or quarterly provider check-ins at $49 to $99 per visit. A "$249/month" medication with mandatory monthly $79 consultations is actually a $328/month program.

The third error is comparing brand-name list prices to compounded cash prices without accounting for insurance. The claim "compound semaglutide is 80% cheaper than Wegovy" is true if you're comparing cash prices. It's false if the patient has insurance covering Wegovy with a $25 copay. The correct comparison is compound cash price vs the patient's actual out-of-pocket cost for the brand, which varies by insurance plan.

Published research on GLP-1 cost-effectiveness (Garvey et al., Obesity 2023) uses brand-name pricing and doesn't account for the compounded market. Cost-effectiveness models built on $1,349/month Wegovy pricing don't translate to $299/month compounded semaglutide scenarios.

The dose-price relationship: why higher doses don't cost proportionally more

The raw ingredient cost of semaglutide does scale with dose. A 2.4 mg vial contains roughly 10 times more active pharmaceutical ingredient (API) than a 0.25 mg vial. But the retail price to patients doesn't scale proportionally.

Typical pricing structure:

Dose	API cost (estimated)	Retail price	Markup ratio
0.25 mg weekly	$12 to $18	$199 to $249	11x to 14x
1.0 mg weekly	$48 to $65	$279 to $349	5x to 6x
2.4 mg weekly	$110 to $145	$399 to $499	3x to 4x

The markup ratio compresses as dose increases because fixed costs (compounding labor, vial, sterility testing, shipping, provider time, platform overhead) don't scale with dose. A 503B pharmacy spends roughly the same labor time compounding a 0.25 mg vial as a 2.4 mg vial. The difference is API cost.

This creates a counterintuitive pricing dynamic: patients at higher doses get better per-milligram value. A patient paying $499/month for 2.4 mg weekly pays $0.21 per microgram. A patient paying $249/month for 0.5 mg weekly pays $0.50 per microgram, more than double the unit cost.

The implication: under-dosing to save money is a false economy. A patient staying at 1.0 mg to avoid the jump to $399/month pricing is paying more per unit of medication and getting less therapeutic effect. The cost-per-pound-lost is higher at lower doses despite lower absolute monthly cost.

Brand-name vs compounded: the real cost comparison

As of April 2026:

Product	Dose	List price (cash)	Typical insurance copay	Compounded equivalent cost
Wegovy (semaglutide)	2.4 mg weekly	$1,349/month	$25 to $1,349 (plan-dependent)	$399 to $499/month
Ozempic (semaglutide)	2.0 mg weekly	$968/month	$25 to $968 (plan-dependent)	$349 to $449/month
Rybelsus (oral semaglutide)	14 mg daily	$935/month	$25 to $935 (plan-dependent)	Not available compounded

The cost advantage of compounded semaglutide is largest for uninsured patients or those with high-deductible plans. A patient paying cash for Wegovy at $1,349/month saves $850 to $950/month by switching to compounded semaglutide at $399 to $499/month.

For patients with insurance covering brand-name GLP-1s, the calculation is different. If your insurance covers Wegovy with a $25 copay, compounded semaglutide at $399/month is more expensive. But coverage is inconsistent. A 2025 analysis by the Kaiser Family Foundation found that only 41% of employer-sponsored health plans cover GLP-1 medications for weight loss as of 2024, and most that do cover require prior authorization and step therapy.

The FDA shortage list is the other variable. Compounded semaglutide is legal under federal law only while brand-name semaglutide appears on the FDA drug shortage list. As of April 2026, semaglutide remains on the shortage list, but Novo Nordisk has stated publicly that supply constraints are easing. If semaglutide is removed from the shortage list, compounding pharmacies will have a 60-day wind-down period before they must stop producing compounded versions.

The pricing landscape could shift rapidly. Patients starting compounded semaglutide in mid-2026 should have a contingency plan for transitioning to brand-name products if compounding becomes unavailable.

Hidden costs that turn a $249 advertised price into $380

The advertised monthly medication cost is rarely the total monthly cost. Common additional fees:

Provider consultation fees:

• Initial consultation: $0 to $149 (often waived with first prescription)
• Monthly follow-up: $0 to $99 per visit
• Quarterly check-in: $49 to $79 per visit
• Asynchronous messaging-only follow-up: typically included

Most platforms require at least quarterly provider contact. A "$249/month medication" with mandatory quarterly $79 visits adds $26/month averaged across the year, making the true cost $275/month.

Lab work:

• Baseline metabolic panel, A1C, lipid panel: $85 to $150 if ordered through the platform
• Follow-up labs at 3 to 6 months: $85 to $150
• Some platforms include lab orders but not lab fees; others bundle lab costs

Shipping:

• Standard shipping: $0 to $15 per shipment
• Expedited shipping: $25 to $40
• Cold-chain shipping (temperature-controlled): $15 to $30

Supplies:

• Syringes and needles: $8 to $15 per month if not included
• Alcohol swabs, sharps container: $5 to $10 one-time
• Most platforms include supplies; some charge separately

Dose adjustment fees:

• Some platforms charge $25 to $49 to change dose mid-cycle
• Others allow unlimited dose adjustments within the subscription

A realistic total monthly cost calculation for a patient at 1.7 mg maintenance dose:

• Medication: $299
• Quarterly provider visit: $79 / 3 months = $26
• Labs twice per year: $150 / 6 months = $25
• Shipping: $15
• Total: $365/month

The advertised $299 became $365 once hidden costs are included. This is not deceptive if the platform discloses fees upfront, but many don't surface the full cost structure until checkout.

The three pricing models: subscription, pay-per-fill, and hybrid

Subscription model:

• Monthly recurring charge, auto-refill
• Medication ships every 28 to 30 days
• Dose adjustments allowed within the subscription tier
• Cancellation policies vary (some require 30-day notice)
• Examples: most telehealth platforms use this model

Advantages: predictable cost, automatic refills, no risk of running out. Disadvantages: harder to pause treatment, cancellation friction, potential for paying during months you don't use medication.

Pay-per-fill model:

• Order each refill individually
• No recurring charge or auto-ship
• Dose adjustments require new prescription
• No cancellation needed (just stop ordering)

Advantages: full control, easy to pause, no subscription lock-in. Disadvantages: risk of running out, must remember to reorder, often higher per-fill cost than subscription pricing.

Hybrid model:

• Subscription for provider access and platform features
• Pay-per-fill for medication
• Common structure: $49 to $99/month membership, then $199 to $399 per medication fill

Advantages: flexibility to skip medication months while maintaining provider access. Disadvantages: two separate charges, higher total cost if you fill medication every month.

The subscription model is cheapest for patients who know they'll stay on treatment continuously for 6+ months. Pay-per-fill is better for patients testing tolerability or planning short-term use. Hybrid models rarely pencil out as cost-effective compared to pure subscription.

Insurance, FSA, and HSA: what's reimbursable and what's not

Insurance coverage: Compounded medications are generally not covered by insurance, even if the brand-name equivalent is covered. The reason: compounded drugs are not FDA-approved, and most insurance formularies only cover FDA-approved medications.

Some exceptions exist. A small number of insurance plans cover compounded medications if the prescriber documents medical necessity (for example, allergy to an inactive ingredient in the brand-name version). This is rare and requires prior authorization.

FSA and HSA eligibility: Compounded semaglutide prescribed for weight loss is eligible for FSA and HSA reimbursement if you have a documented medical condition. IRS Publication 502 allows medical expense deductions for obesity treatment if a physician diagnoses obesity as a disease.

The key requirement: a formal diagnosis. A prescription alone is not sufficient. The provider must document a diagnosis of obesity (BMI ≥ 30) or overweight with comorbidity (BMI ≥ 27 with hypertension, diabetes, dyslipidemia, or sleep apnea).

With proper documentation:

• Medication cost: HSA/FSA eligible
• Provider consultation fees: HSA/FSA eligible
• Lab work: HSA/FSA eligible
• Shipping: typically not eligible (administrative fee, not medical expense)

Most platforms provide itemized receipts suitable for HSA/FSA submission. Some integrate directly with HSA/FSA card processors, allowing you to pay with your HSA card at checkout.

Tax deduction: Medical expenses exceeding 7.5% of adjusted gross income are tax-deductible. For a patient with $80,000 AGI, expenses beyond $6,000 are deductible. If you spend $4,800/year on compounded semaglutide, it won't clear the threshold alone, but combined with other medical expenses it might.

Geographic price variation and pharmacy sourcing

Compounded semaglutide pricing shows minimal geographic variation compared to other prescription medications. The reason: most telehealth platforms ship from a single 503B outsourcing facility regardless of patient location.

A patient in rural Montana pays the same price as a patient in Manhattan because both receive medication from the same compounding pharmacy in Florida, Texas, or Tennessee (the states with the largest 503B facilities).

The exception: state-specific telehealth platforms that use local 503A compounding pharmacies. These sometimes have higher costs due to smaller batch sizes and higher state-level regulatory overhead. A 503A pharmacy in California compounding individual prescriptions may charge $50 to $100 more per month than a 503B facility in Texas producing larger batches.

Pharmacy sourcing affects price in two ways:

1. 503A vs 503B regulatory pathway. 503B outsourcing facilities can produce larger batches and distribute across state lines without individual prescriptions in hand. This creates economies of scale. 503A pharmacies compound individual prescriptions and can't produce in advance, raising per-unit costs.

1. API source. Semaglutide API is manufactured by a small number of suppliers, mostly in China and India. Pharmacies using API from FDA-registered facilities with full documentation pay more than those using cheaper sources with less rigorous documentation. The price difference in raw API can be $50 to $100 per gram, which translates to $10 to $20 per patient per month.

Most reputable platforms use 503B pharmacies with API sourced from FDA-registered suppliers. Platforms advertising prices below $199/month for maintenance doses often use 503A pharmacies with lower-cost API, which may carry higher contamination or potency variation risk.

The FormBlends pricing framework: how we think about transparent cost structure

At FormBlends, we see three patterns in how patients evaluate cost:

Pattern 1: The monthly-payment shopper. Focuses on the advertised monthly price. Chooses the lowest number. Often surprised by hidden fees or dose-escalation price jumps. Switches platforms 2 to 3 times in the first 6 months chasing lower advertised prices, which disrupts treatment continuity.

Pattern 2: The total-cost-of-ownership calculator. Builds a spreadsheet. Includes medication, consultations, labs, shipping, and expected dose escalation over 12 months. Chooses based on projected annual cost, not monthly cost. Stays with one platform longer. Better treatment adherence.

Pattern 3: The value-per-outcome optimizer. Calculates cost per pound lost or cost per A1C point reduced. Willing to pay more per month if the platform provides better support, faster dose titration, or higher treatment success rates. Focuses on the cost of NOT losing weight (comorbidity costs, quality of life) rather than the cost of medication.

The pattern we see most often: patients start as Pattern 1 shoppers, switch platforms once or twice, then convert to Pattern 2 calculators after experiencing hidden fees.

Our pricing model is designed for Pattern 2 and 3 patients:

• Transparent tiered pricing with no hidden consultation fees
• All supplies included (syringes, needles, alcohol swabs, sharps container)
• Free standard shipping
• Unlimited messaging with providers (no per-message fees)
• Quarterly video visits included in medication cost
• Labs ordered at cost (we don't mark up lab fees)

A patient at 1.7 mg maintenance pays $349/month, and that's the actual total monthly cost. No surprise fees at month 3.

[Diagram suggestion: Three-column comparison table showing "Advertised price," "Hidden fees," and "True monthly cost" for a typical competitor vs FormBlends, with line items for medication, consultation, labs, shipping, and supplies]

When cheaper is actually more expensive: the false economy of under-dosing

The most expensive way to use compounded semaglutide is to under-dose to save money.

Example: A patient reaches 1.0 mg weekly and experiences good appetite suppression and 1.5 pounds per week weight loss. The provider recommends escalating to 1.7 mg to maintain momentum. The patient sees that 1.7 mg costs $349/month vs $299/month for 1.0 mg and decides to stay at 1.0 mg.

Over the next 8 weeks, weight loss slows to 0.5 pounds per week as the body adapts to 1.0 mg. The patient loses 4 pounds instead of the 12 pounds they would have lost at 1.7 mg. The $50/month savings cost them 8 pounds of progress.

The cost per pound lost:

• At 1.7 mg, $349/month, 1.5 lb/week average: $58 per pound lost
• At 1.0 mg, $299/month, 0.5 lb/week average: $149 per pound lost

The cheaper dose is 2.5 times more expensive per unit of outcome.

This pattern appears in the STEP trial data. Patients who reached and maintained 2.4 mg semaglutide lost an average of 14.9% of body weight over 68 weeks (Wilding et al., New England Journal of Medicine 2021). Patients who stopped at lower doses lost 8% to 11%. The cost per percentage point of weight loss is lower at higher doses despite higher absolute monthly cost.

The same logic applies to treatment duration. A patient who stays on semaglutide for 12 months and loses 40 pounds spends $3,600 to $5,000 total. A patient who quits after 3 months due to cost concerns, loses 12 pounds, regains 8 pounds, then restarts 6 months later spends less in absolute dollars but achieves worse outcomes. The cost per sustained pound lost is higher.

The decision tree: if you can afford 6 to 12 months of treatment at maintenance dose, start. If you can only afford 2 to 3 months, consider waiting until your financial situation allows longer treatment. The outcome data for short-duration GLP-1 use shows poor durability (Wilding et al., Lancet 2022).

How to calculate your true monthly cost

Use this framework to calculate what you'll actually pay:

Step 1: Determine your expected maintenance dose. Most patients reach maintenance at 1.7 mg to 2.4 mg weekly. If you're starting treatment, assume you'll escalate to at least 1.7 mg by month 4 to 5. Use that dose tier for cost calculation, not the starting dose.

Step 2: Find the medication cost at that dose tier. Check the platform's pricing page. Look for "1.7 mg weekly" or "2.4 mg weekly" pricing, not the advertised starting price.

Step 3: Add consultation fees.

• If monthly visits are required: add the per-visit fee
• If quarterly visits: divide the per-visit fee by 3
• If included: add $0

Step 4: Add lab costs. Most platforms require labs at baseline and 3 to 6 months. Assume 2 lab panels per year at $100 to $150 each. Divide by 12 months.

Step 5: Add shipping. If not included, add $10 to $15 per month.

Step 6: Add supplies. If syringes and needles aren't included, add $10 per month.

Example calculation for a patient reaching 1.7 mg maintenance:

• Medication at 1.7 mg tier: $349
• Quarterly visits at $79 each: $79 / 3 = $26
• Labs twice per year at $125 each: $250 / 12 = $21
• Shipping: included ($0)
• Supplies: included ($0)
• Total: $396/month

Multiply by 12 to get annual cost: $4,752.

Compare this to brand-name Wegovy at $1,349/month: $16,188 per year. The compounded version saves $11,436 annually at this dose.

FAQ

How much does compound semaglutide cost per month?

Compound semaglutide costs $199 to $499 per month depending on dose. Starting doses (0.25 mg to 0.5 mg weekly) cost $199 to $249. Maintenance doses (1.7 mg to 2.4 mg weekly) cost $349 to $499. Add $50 to $100 per month for consultation fees, labs, and shipping at most platforms.

Is compound semaglutide cheaper than Wegovy?

Yes. Wegovy costs $1,349 per month without insurance. Compound semaglutide at equivalent dose (2.4 mg weekly) costs $399 to $499 per month, a savings of $850 to $950 monthly. If your insurance covers Wegovy with a low copay, the brand-name version may be cheaper.

Why does compound semaglutide cost less than brand-name versions?

Compounded medications skip the FDA approval process, clinical trials, marketing costs, and brand markup that drive up brand-name drug prices. Compounding pharmacies produce medication in response to individual prescriptions at lower overhead cost. The active ingredient is the same, but the regulatory and business model is different.

Does insurance cover compound semaglutide?

Generally no. Most insurance plans only cover FDA-approved medications, and compounded drugs are not FDA-approved. Some plans cover compounded medications with prior authorization if the prescriber documents medical necessity, but this is rare. Check with your insurance provider.

Can I use my HSA or FSA to pay for compound semaglutide?

Yes, if you have a documented medical diagnosis of obesity or overweight with comorbidity. The provider must document a formal diagnosis, not just write a prescription. With proper documentation, medication costs, consultation fees, and lab work are HSA/FSA eligible.

How much is compound semaglutide at the highest dose?

Compound semaglutide at 2.4 mg weekly (the maximum dose) costs $399 to $499 per month at most platforms as of April 2026. This is the same dose as brand-name Wegovy, which costs $1,349 per month without insurance.

What's the cheapest way to get compound semaglutide?

The lowest advertised prices ($199 to $249 per month) apply only to starting doses (0.25 mg to 0.5 mg weekly). To minimize total cost: choose a subscription platform with no consultation fees, dose up to the minimum effective dose for your goals (don't over-dose), and use a platform that includes shipping and supplies.

Do compound semaglutide prices include syringes and needles?

It depends on the platform. Most include syringes, needles, and alcohol swabs in the medication price. Some charge separately ($8 to $15 per month). Check the platform's pricing page or ask during the initial consultation.

How much does compound semaglutide cost for the first month?

First-month cost is typically $199 to $249 for medication at the starting dose (0.25 mg weekly), plus $0 to $149 for the initial consultation (often waived), plus $0 to $150 for baseline labs if required. Total first-month cost: $199 to $550 depending on the platform.

Is compound semaglutide still available in 2026?

Yes, as of April 2026. Compounded semaglutide is legal while brand-name semaglutide remains on the FDA drug shortage list. Novo Nordisk has indicated supply is improving, and the FDA may remove semaglutide from the shortage list in late 2026 or 2027, which would end legal compounding after a 60-day transition period.

How does compound semaglutide cost compare to Ozempic?

Ozempic costs $968 per month without insurance. Compound semaglutide at equivalent dose (2.0 mg weekly) costs $349 to $449 per month, a savings of $519 to $619 monthly. Ozempic is FDA-approved for diabetes, not weight loss, so insurance coverage varies.

What's the average cost of compound semaglutide over a full year?

Average annual cost is $3,600 to $5,500 depending on dose escalation timeline and platform fees. Patients typically spend 2 to 3 months at starting-dose pricing ($199 to $249/month), then 9 to 10 months at maintenance-dose pricing ($299 to $499/month). Include consultation fees and labs for total cost.

Related guides

• How Much Is Zepbound on LillyDirect: Real Pricing, Hidden Costs, and the Math vs Compounded Tirzepatide
• How Much Will Zepbound Be on Trump Rx: Real Pricing Data and What Actually Changed
• How Much Ozempic Costs in Canada: Provincial Coverage Breakdown, Out-of-Pocket Pricing, and the Math on Cross-Border Compounded Alternatives
• How Much Weight Can You Lose on Mounjaro 5 mg? Real-World Data and Clinical Patterns
• How Much Is Zepbound in Mexico: Real Pricing, Legal Risks, and Why the Math Doesn't Work the Way You Think
• What Phentermine Actually Costs in 2026: The Complete Pricing Breakdown for Brand, Generic, and Compounded Options
• Tool: dosage calculator

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Lancet. 2022.
3. Garvey WT et al. Cost-effectiveness of once-weekly semaglutide for weight management. Obesity. 2023.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. FDA Drug Shortages Database. Semaglutide injection status. Updated April 2026.
6. Kaiser Family Foundation. Employer Health Benefits Survey 2024. GLP-1 coverage analysis.
7. IRS Publication 502. Medical and Dental Expenses. 2025 edition.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
11. Novo Nordisk investor relations. Wegovy and Ozempic supply update Q1 2026.
12. FDA guidance for industry. Compounding and the FDA. Updated January 2026.
13. National Association of Boards of Pharmacy. 503A vs 503B compounding facilities. 2025.
14. American Society of Health-System Pharmacists. Drug shortage management guidelines. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.